Jump to Navigation

Lyrica Fact Sheet

Printer-friendly version
Medication Name (brand): 
Medication Name (clinical): 


  • Diabetic neuropathic pain, post-herpetic neuralgia, and adjunctive treatment of epilepsy.

  • Approved for generalized anxiety disorder (GAD) in Europe as of March 2006.


Enhances presynaptic release of GABA; close chemical cousin of Neurontin (gabapentin).

  • Supplied in 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg capsules.

  • Dosing recommendations based on controlled trials for GAD: Start at around 100 mg BID and increase as tolerated to a maximum of 300 mg BID.
  • No dose adjustment required in liver impairment. Reduce dose in patients with renal impairment and in elderly with some degree of renal impairment.

Side Effects: 
  • High rates of dizziness (about 30%) and sedation (22%).

  • Other common side effects: blurred vision, weight gain of about 5 pounds, peripheral edema, and impaired concentration/attention.
  • Has some limited abuse liability and is a Schedule V controlled substance (in the same category as cough suppressants containing codeine). Can cause a withdrawal syndrome of nausea, insomnia and headache if not gradually tapered.

Drug-drug Interactions: 
  • No drug-drug interactions.

  • Not metabolized by the liver, is excreted unchanged by the kidney.


Half-life 6 hours.

Return to issue area